CyDex Pharmaceuticals Inc., a Lenexa, Kansas-based developer of drugs that “address limitations of current therapies in selected established,” has withdrawn registration of its $50 million IPO. It had planned to trade on the Nasdaq, with Pacific Growth Equities serving as lead underwriter. 

 

CyDex has raised over $29 million in VC funding since 2000, from firms like TVM Capital, RiverVest Venture Partners, Life Sciences Opportunities Funds, S.R. One Ltd. and Eastman Chemical Company Investments. www.cydexinc.com

Related posts:

  1. CyDex Files for IPO
  2. Aldagen Cancels IPO
  3. Salient Surgical Cancels IPO
  4. Sonics Cancels IPO
  5. RiverVest to Open Office in Cleveland